NVO250103P71000
- 0.00
- 0.000.00%
Novo-Nordisk A/S Newsroom
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
Novo Nordisk Shares Are Trading Higher After the Company Entered Into an Expanded Agreement With Valo Health to Discover and Develop Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease.
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
Ozempic Maker Novo Nordisk, After Trial Disappointment, Expands AI Deal in Potential $4.6 Billion Pact
Facebook Moderation Move Is a Mistake. Why -2-
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk Raised to Buy From Neutral by UBS
Novo Nordisk Target Cut to DKK750 From DKK1,100 by UBS
Novo Nordisk Needs Answers to These 5 Key Questions
Danish Stocks Mixed as Trump Threatens Tariffs to Acquire Greenland
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Variant Bio Announces Multi-Year Research Partnership With Novo Nordisk to Discover Novel Targets for Metabolic Disease
Top Gap Ups and Downs on Monday: TSM, NVO, PG and More
European Equities Traded in US as American Depositary Receipts Surge on Monday
Berenberg Cuts Novo Nordisk's Price Target After 'Disappointing' Weight-loss Drug Trial Results
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk (0QIU) Gets a Hold From Berenberg Bank
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Novo Nordisk Seeks to Block Compounded Victoza
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer